Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2016

09.09.2016 | Urologic Oncology

Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History

verfasst von: Hiroki Ide, MD, Eiji Kikuchi, MD, PhD, Masayuki Hagiwara, MD, Nozomi Hayakawa, MD, Hiroshi Hongo, MD, Akira Miyajima, MD, PhD, Mototsugu Oya, MD, PhD

Erschienen in: Annals of Surgical Oncology | Sonderheft 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Aromatic amines, well-known bladder carcinogens, derived from cigarette smoke are activated by acidic urine. We herein determined whether urinary pH levels are associated with bladder recurrence in upper tract urothelial carcinoma patients with a positive smoking history.

Methods

A total of 256 upper tract urothelial carcinoma patients who were surgically treated at our institution between 1990 and 2013 were included. Urinary pH levels were defined as the median of at least two consecutive measurements within 1 month of surgery.

Results

Ninety-six patients (37.5 %) had pH <5.5 and 160 (62.5 %) had pH ≥5.5, and urinary pH levels were identified as one of the significant predictors for bladder recurrence in univariate but not multivariate Cox regression analysis in overall. In patients with a positive smoking history among those without a history of bladder tumor (N = 110), the 5-year bladder recurrence-free survival rate was 52.5 % in patients with pH ≥5.5, which was significantly higher than that in those with pH <5.5 (25.9 %, p = 0.032). In the multivariate analysis, urinary pH <5.5 (p = 0.022, HR; 1.86) was independently associated with bladder recurrence. No significant difference for bladder recurrence was observed between these two groups in patients with no smoking history among them.

Conclusions

Urinary pH <5.5 is associated with an increased risk of bladder recurrence in upper tract urothelial carcinoma patients with a positive smoking history among those without a history of bladder tumor. Modifications to pH for urine alkalization may prevent bladder recurrence.
Literatur
1.
Zurück zum Zitat Oosterlinck W. Ureteral tumour: a specific upper urinary tract transitional cell carcinoma. Eur Urol. 2007;51(5):1164–5.CrossRefPubMed Oosterlinck W. Ureteral tumour: a specific upper urinary tract transitional cell carcinoma. Eur Urol. 2007;51(5):1164–5.CrossRefPubMed
2.
Zurück zum Zitat Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRefPubMed Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRefPubMed
3.
Zurück zum Zitat Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61(4):818–25.CrossRefPubMed Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61(4):818–25.CrossRefPubMed
4.
Zurück zum Zitat Zhang Z, Fang D, Chen X, et al. Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: experience from a nationwide high-volume center in China. Oncol Lett. 2015;10(5):3113–22.PubMedPubMedCentral Zhang Z, Fang D, Chen X, et al. Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: experience from a nationwide high-volume center in China. Oncol Lett. 2015;10(5):3113–22.PubMedPubMedCentral
5.
Zurück zum Zitat Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol. 2010;58(5):645–51.CrossRefPubMedPubMedCentral Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol. 2010;58(5):645–51.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian upper tract collaboration. Urol Oncol. 2014;32(6):839–45.CrossRefPubMed Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian upper tract collaboration. Urol Oncol. 2014;32(6):839–45.CrossRefPubMed
7.
Zurück zum Zitat Ishioka J, Saito K, Kijima T, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2015;115(5):705–12.CrossRefPubMed Ishioka J, Saito K, Kijima T, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2015;115(5):705–12.CrossRefPubMed
8.
Zurück zum Zitat Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98(6):1181–6.CrossRefPubMed Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98(6):1181–6.CrossRefPubMed
9.
Zurück zum Zitat Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–34.CrossRefPubMed Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–34.CrossRefPubMed
10.
Zurück zum Zitat Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol. 2008;15(9):800–3.CrossRefPubMed Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol. 2008;15(9):800–3.CrossRefPubMed
11.
Zurück zum Zitat Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. 2013;31(6):899–903.CrossRefPubMed Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. 2013;31(6):899–903.CrossRefPubMed
12.
Zurück zum Zitat Seisen T, Granger B, Colin P, et al. A Systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122–33.CrossRefPubMed Seisen T, Granger B, Colin P, et al. A Systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122–33.CrossRefPubMed
13.
Zurück zum Zitat Sankin A, Tin AL, Mano R, et al. Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. Urology. 2016;94:148–53.CrossRefPubMed Sankin A, Tin AL, Mano R, et al. Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. Urology. 2016;94:148–53.CrossRefPubMed
14.
Zurück zum Zitat Hagiwara M, Kikuchi E, Tanaka N, et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2013;189(6):2062–8.CrossRefPubMed Hagiwara M, Kikuchi E, Tanaka N, et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2013;189(6):2062–8.CrossRefPubMed
15.
Zurück zum Zitat O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of O. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial). Eur Urol. 2011;60(4):703–10.CrossRefPubMed O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of O. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial). Eur Urol. 2011;60(4):703–10.CrossRefPubMed
16.
Zurück zum Zitat Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31(11):1422–7.CrossRefPubMed Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31(11):1422–7.CrossRefPubMed
17.
Zurück zum Zitat Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 1991;51(19):5144–52.PubMed Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 1991;51(19):5144–52.PubMed
18.
Zurück zum Zitat Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J Urol. 2011;185(3):802–6.CrossRefPubMed Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J Urol. 2011;185(3):802–6.CrossRefPubMed
19.
Zurück zum Zitat Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 1977;37(3):805–14.PubMed Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 1977;37(3):805–14.PubMed
20.
Zurück zum Zitat Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochem Pharmacol. 1996;51(12):1679–85.CrossRefPubMed Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochem Pharmacol. 1996;51(12):1679–85.CrossRefPubMed
21.
22.
Zurück zum Zitat Zenser TV, Lakshmi VM, Hsu FF, Davis BB. Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res. 2002;506–507:29–40.CrossRefPubMed Zenser TV, Lakshmi VM, Hsu FF, Davis BB. Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res. 2002;506–507:29–40.CrossRefPubMed
23.
Zurück zum Zitat Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901–7.CrossRefPubMedPubMedCentral Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901–7.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Babu SR, Lakshmi VM, Hsu FF, Kane RE, Zenser TV, Davis BB. N-acetylbenzidine-N’-glucuronidation by human, dog and rat liver. Carcinogenesis. 1993;14(12):2605–11.CrossRefPubMed Babu SR, Lakshmi VM, Hsu FF, Kane RE, Zenser TV, Davis BB. N-acetylbenzidine-N’-glucuronidation by human, dog and rat liver. Carcinogenesis. 1993;14(12):2605–11.CrossRefPubMed
25.
Zurück zum Zitat Lakshmi VM, Hsu FF, Zenser TV. Transformation and activation of benzidine by oxidants of the inflammatory response. Chem Res Toxicol. 2003;16(3):367–74.CrossRefPubMed Lakshmi VM, Hsu FF, Zenser TV. Transformation and activation of benzidine by oxidants of the inflammatory response. Chem Res Toxicol. 2003;16(3):367–74.CrossRefPubMed
26.
Zurück zum Zitat Bois FY, Krowech G, Zeise L. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. Risk Anal. 1995;15(2):205–13.CrossRefPubMed Bois FY, Krowech G, Zeise L. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. Risk Anal. 1995;15(2):205–13.CrossRefPubMed
27.
Zurück zum Zitat Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013;91(3):291–6.CrossRefPubMed Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013;91(3):291–6.CrossRefPubMed
28.
Zurück zum Zitat Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.CrossRefPubMed Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.CrossRefPubMed
29.
Zurück zum Zitat Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–68.CrossRefPubMed Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–68.CrossRefPubMed
Metadaten
Titel
Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History
verfasst von
Hiroki Ide, MD
Eiji Kikuchi, MD, PhD
Masayuki Hagiwara, MD
Nozomi Hayakawa, MD
Hiroshi Hongo, MD
Akira Miyajima, MD, PhD
Mototsugu Oya, MD, PhD
Publikationsdatum
09.09.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 5/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5555-y

Weitere Artikel der Sonderheft 5/2016

Annals of Surgical Oncology 5/2016 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.